<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796315</url>
  </required_header>
  <id_info>
    <org_study_id>2008014</org_study_id>
    <nct_id>NCT00796315</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children</brief_title>
  <official_title>A Single-dose, Open-label, Multi-center Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Ages 2 to &lt; 18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consumer Healthcare Products Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Procter and Gamble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to characterize the pharmacokinetics of doxylamine
      succinate in children ages 2 to &lt; 18 years. Once characterized, these pediatric
      pharmacokinetic data will be pooled with historical adult PK data from other studies to
      assess whether the existing Over-the-Counter (OTC)doses provide comparable systemic drug
      exposure as that associated with efficacy in adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of Doxylamine</measure>
    <time_frame>72 Hours</time_frame>
    <description>Area under the time-concentration curve for Doxylamine from 0 to 72 hours post-dose plus an extrapolated area from 72 hours to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Doxylamine</measure>
    <time_frame>72 Hours</time_frame>
    <description>Maximum concentration of Doxylamine from 0 to 72 hours post-dose</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Upper Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Doxylamine Succinate (USP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxylamine Succinate United States Pharmacopeia (USP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxylamine Succinate USP</intervention_name>
    <description>One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL</description>
    <arm_group_label>Doxylamine Succinate (USP)</arm_group_label>
    <other_name>Doxylamine Succinate United States Pharmacopeia (USP)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  are male or female children ages 2 to &lt; 18 years, with a minimum weight of 24 lbs and
             &gt; 5th percentile and &lt; 95th percentile for weight based on age and sex, at the time of
             dosing study medication

          -  had a previous diagnosis of allergic rhinitis, or had a history of frequent upper
             respiratory infections (URI)/common cold and either be symptomatic, or at risk for
             future URI, including each of the following 3 criteria

               -  Frequency Criterion: &gt; 6 infections per year for children aged 2 to &lt;6 years of
                  age and &gt; 4 infections per year for children aged 6 to &lt; 18 years of age

               -  Crowding Criterion: 4 persons living in the home or 3 persons sleeping in one
                  bedroom

               -  Exposure Criterion: another family member in the home who is ill with URI /
                  common cold or a child in the family who is attending preschool or school with 6
                  children in the group.

          -  are in good general health

          -  are likely to be compliant and complete the study and have parent(s) or legally
             authorized representative(s) likely to be compliant and complete the study according
             to the Investigator

          -  whose parent(s) or legally authorized representative(s) have signed and dated an
             Institutional Review Board (IRB)-approved consent form for the subject to participate
             in the study

          -  must have signed an assent form as required by the site's IRB

          -  if post-menarchal females, subjects must have a negative urine pregnancy test at
             screening and check-in, or serum pregnancy test at screening, if site required;

          -  if post-menarchal females, subjects must practice abstinence or use an effective form
             of birth control (eg, intrauterine device, low dose oral contraceptives [ 50g ethinyl
             estradiol], contraceptive implants or injections, diaphragm with spermicide, cervical
             cap, or consort use of condom) for at least 3 months before being enrolled in the
             study.

        Exclusion Criteria:

          -  has any history or presence of the following medical conditions: peptic ulcer,
             pyloroduodenal obstruction or other gastrointestinal disease; renal or hepatic
             disease; diabetes mellitus; hyperthyroidism; cardiovascular disease;increased ocular
             pressure or glaucoma; endocrine, metabolic, hematologic or neoplastic disease; seizure
             disorder; chronic respiratory diseases including asthma, emphysema and chronic
             bronchitis; autoimmune disease; immunodeficiency tuberculosis; bladder neck
             obstruction; significant dermatologic condition.

          -  has a known sensitivity or allergy to doxylamine succinate

          -  has a history of a severe allergic reaction to any drug or has multiple food/drug
             allergies

          -  experienced febrile illness greater than 100Â°F within 7 days prior to dosing

          -  reports any known enzyme-inducer, enzyme-inhibitor, or reported chronic exposure to
             enzyme-inducers such as paint solvents or pesticides within 30 days prior to dosing,
             unless approved by the Sponsor

          -  reports any other prescription drug or herbal remedy usage within 14 days prior to
             dosing except for low dose contraceptives, unless approved by the Sponsor

          -  reports any non-prescription drug or supplemental vitamin usage within 5 days prior to
             dosing

          -  unwillingness to refrain from caffeine or other xanthine-containing beverages,
             including coffee and tea, alcohol, grapefruit juice, chocolate, or Seville oranges 24
             hours prior to admission and throughout the study

          -  reported use of tobacco, smoking cessation products, or products containing nicotine
             within 3 months prior to Screening

          -  has an acute illness (except as described in Section 3.3.1 Inclusion Criterion b)
             within 14 days prior to dosing; unless approved by the Sponsor;

          -  has any laboratory value outside the laboratory reference range considered clinically
             significant by the Investigator

          -  has a history or diagnosis of Hepatitis B, Hepatitis C, human immunodeficiency virus
             (HIV), or thyroid disease

          -  has a history of alcohol or illicit drug use or a positive urine drug of abuse screen

          -  are pregnant or lactating (post-menarchal female subjects should be made aware that
             pregnancy testing will occur during the study, and that if they are sexually active
             they must take appropriate steps to ensure they do not become pregnant during the
             study)

          -  has made a blood donation or plasma donation within 4 weeks prior to dosing;

          -  has participated in another investigational drug study protocol within 30 days prior
             to dosing (Day -1)

          -  has a history or presence, upon clinical evaluation, of any illness or condition that
             might impact safety of the subject with test product administration or evaluability of
             drug effect, based on the Investigator's discretion

          -  is unable to avoid driving, operating machinery, or other tasks that require alertness
             during the study.

          -  is unable or unwilling to avoid contact sports, strenuous exercises (e.g. weight
             lifting), exercises for which they are not trained or conditioned or intramuscular
             injection for at least 1 week before baseline visit when creatine phosphokinase (CPK)
             will be evaluated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Molly Seeck, BS, JD</last_name>
    <role>Study Director</role>
    <affiliation>Procter and Gamble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Best, MD</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janice E. Sullivan, MD</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret Ann Springer, MD</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgette Jones, MD</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alex Kemper, Pharm D</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey L Blumer, MD, PhD</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <results_first_submitted>December 19, 2012</results_first_submitted>
  <results_first_submitted_qc>December 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2013</results_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxylamine</mesh_term>
    <mesh_term>Doxylamine succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participant flow is described by three different age groups based on dosing differences for each group</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects Aged 2-5 Years (Doxylamine Succinate)</title>
          <description>Ages 2-5 years. Doxylamine Succinate USP : One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL.</description>
        </group>
        <group group_id="P2">
          <title>Aged 6-11 Years (Doxylamine Succinate</title>
          <description>Ages 6-11 years. Doxylamine Succinate USP : One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL.
Note: One subject (age group 6-11) was unable to meet protocol criteria (spit out a portion of his dosage) and was discontinued.</description>
        </group>
        <group group_id="P3">
          <title>Subjects Aged 12-17 Years (Doxylamine Suc</title>
          <description>Ages 12-17 years. Doxylamine Succinate USP : One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxylamine Succinate USP</title>
          <description>Doxylamine Succinate, United States Pharmacopeia (USP): One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Subjects Aged 2-5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects Aged 6-11 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects Aged 12-17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male, Ages 2-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female, Ages 2-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male, Ages 6-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female, Ages 6-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male, Ages 12-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female, Ages 12-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC of Doxylamine</title>
        <description>Area under the time-concentration curve for Doxylamine from 0 to 72 hours post-dose plus an extrapolated area from 72 hours to infinity.</description>
        <time_frame>72 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects Aged 2-5 Years</title>
            <description>Ages 2-5 years. Subjects received a dose of either 3.125 or 4.17 mg Doxylamine Succinate USP (exact dose dependent upon body weight)</description>
          </group>
          <group group_id="O2">
            <title>Subjects Aged 6-11 Years</title>
            <description>Ages 6-11 years. Subjects received a dose of 4.17 or 6.25 or 8.33 or 10.42 mg Doxylamine Succinate USP (exact dose dependent upon body weight). Note: One subject (age group 6-11) was unable to meet protocol criteria (spit out a portion of his dosage) and was discontinued.</description>
          </group>
          <group group_id="O3">
            <title>Subjects Aged 12-17 Years</title>
            <description>Ages 12-17 years. All subjects received a dose of 12.5 mg Doxylamine Succinate USP</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Doxylamine</title>
          <description>Area under the time-concentration curve for Doxylamine from 0 to 72 hours post-dose plus an extrapolated area from 72 hours to infinity.</description>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461.9" spread="51.2"/>
                    <measurement group_id="O2" value="810.1" spread="27.9"/>
                    <measurement group_id="O3" value="827.0" spread="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Doxylamine</title>
        <description>Maximum concentration of Doxylamine from 0 to 72 hours post-dose</description>
        <time_frame>72 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects Aged 2-5 Years</title>
            <description>Ages 2-5 years. Doxylamine Succinate USP</description>
          </group>
          <group group_id="O2">
            <title>Subjects Aged 6-11 Years</title>
            <description>Ages 6-11 years. Doxylamine Succinate USP</description>
          </group>
          <group group_id="O3">
            <title>Subjects Aged 12-17 Years</title>
            <description>Ages 12-17 years. Doxylamine Succinate USP</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Doxylamine</title>
          <description>Maximum concentration of Doxylamine from 0 to 72 hours post-dose</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" spread="22.5"/>
                    <measurement group_id="O2" value="65.8" spread="19.9"/>
                    <measurement group_id="O3" value="63.2" spread="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events collected until discharge from study, approximately 72 hours after dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subjects Aged 2-5 Years</title>
          <description>Ages 2-5 years. Doxylamine Succinate USP</description>
        </group>
        <group group_id="E2">
          <title>Aged 6-11 Years</title>
          <description>Ages 6-11 years. Doxylamine Succinate USP</description>
        </group>
        <group group_id="E3">
          <title>Subjects Aged 12-17 Years</title>
          <description>Ages 12-17 years. Doxylamine succinate USP</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Medra</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator and Sub-Investigators agree that all data, calculations, interpretations, opinions, and recommendations regarding the study will be the property of the Sponsor. The Investigator agrees to consider the results as information subject to confidentiality and use restrictions.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Incidences of mild sedation are consistent with doxylamine's indication as an OTC sleep aid. Conclusive evaluation of sedation couldn't be undertaken in the absence of a control group. Also, children may nap in daytime confounding sedation assessment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Guhan Balan</name_or_title>
      <organization>Procter &amp; Gamble</organization>
      <phone>513.622.2657</phone>
      <email>balan.g@pg.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

